You are here

  • Home
  • Archive
  • Volume 78, Issue 5
  • Response to: ’A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease' by Aeschlimann et al

Article info

Article menu

Download PDFPDF

Correspondence response
Response to: ’A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease' by Aeschlimann et al
Free

Authors

  • Florence A Aeschlimann Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario, Canada Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada PubMed articlesGoogle scholar articles
  • Ronald M Laxer Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario, Canada Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada Department of Medicine, University of Toronto, Toronto, Ontario, Canada PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Florence A Aeschlimann, Division of Rheumatology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; florence.aeschlimann{at}aphp.fr
View Full Text

Citation

Aeschlimann FA, Laxer RM
Response to: ’A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease' by Aeschlimann et al
Annals of the Rheumatic Diseases 2019;78:e36.

Publication history

  • Received March 16, 2018
  • Accepted March 16, 2018
  • First published March 24, 2018.
Online issue publication 
October 26, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.